Nobel Biocare reinforces leading market position in Asia by establishing own subsidiary in Taiwan
Taiwan: An attractive market with strong prospects
The Taiwanese dental market comprises over 10,000 dentists and 2,000 labs, serving a population of 23 million people. Approximately 15% (>3 million) of the Taiwanese population is estimated to be missing one or more teeth. Less than 5% of them have been treated with implants so far. Current implant market volume is estimated at ~USD 50 million. Taiwan is considered one of the most attractive dental markets in Asia.
Continued investments in market growth initiatives in Asia
The Taiwanese subsidiary marks another milestone in Nobel Biocare's continued investment into the promising Asia region and is a further step towards increasing the company's global reach, and strengthening its leading position in Asia. With the strongest regional presence in the industry, Nobel Biocare is well positioned to capitalize on the growth drivers of this attractive region.
During the past two years, Nobel Biocare has successfully opened subsidiaries in key Asian markets, including China and India. In 2007, the company also inaugurated the first Asian Procera production facility for individualized full-ceramic prosthetics in Tokyo. In parallel with the inauguration, an esthetic and restorative dental conference was held, at which more than 2,000 Japanese dental professionals were in attendance. Nobel Biocare holds a 32% percent market share in Japan, the largest Asian market.
The company reinforces its market growth initiatives in Asia by investing in training and education initiatives, such as World Tour conferences and strategic university partnerships. In April and May 2008, the company hosted two successful World Tour conferences in Shanghai (China) and Mumbai (India). In addition, two major World Tour conferences are scheduled for the end of June in Singapore, and in September in Taiwan.
Largest geographical presence
With its Taiwanese subsidiary, Nobel Biocare has expanded its global reach to 37 company-owned organizations, and its products and services are available in 70 countries. The company maintains the largest geographical foothold in the industry, and its global reach comprises a direct presence and leading positions in key emerging markets in Asia, Latin America and Eastern Europe. Currently, Asia contributes 15% to Nobel Biocare's sales and should become an increasingly important driver for growth in the future.
Nobel Biocare Deutschland GmbH
Nobel Biocare is a medical devices group and the world leader in innovative esthetic dental solutions with its brands NobelActive(TM) , Brånemark System®, NobelReplace(TM) , NobelSpeedy(TM) , NobelPerfect®, NobelDirect®, Replace Select (dental implants), Procera® (individualized dental prosthetics), NobelGuide(TM) (complete patient rehabilitation program) and NobelSmile(TM) (patient education and awareness program). Nobel Biocare is a full solution provider for restorative esthetic dentistry, offering a wide range of innovative Crown & Bridge & Implant products, as well as training and education, patient information and clinically documented treatment concepts. Nobel Biocare has over 2,500 employees and recorded revenue of EUR 665.9 million in 2007. The Company is domiciled and headquartered in Zurich, Switzerland. Production takes place at six production sites located in Sweden, the US, Japan and Israel. Nobel Biocare has 37 direct sales organizations. The shares of the parent company Nobel Biocare Holding AG are listed on the SWX Swiss Exchange.